S&P 500   4,592.41 (-1.35%)
DOW   34,632.41 (-1.43%)
QQQ   393.90 (-1.45%)
AAPL   163.94 (+2.31%)
MSFT   331.12 (-1.64%)
FB   327.49 (-3.12%)
GOOGL   2,850.95 (-2.05%)
AMZN   3,508.17 (-1.50%)
TSLA   1,132.11 (-0.43%)
NVDA   322.53 (-3.36%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.46 (-5.42%)
AMD   157.27 (-2.87%)
GE   94.86 (-3.60%)
MU   84.83 (-1.52%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,592.41 (-1.35%)
DOW   34,632.41 (-1.43%)
QQQ   393.90 (-1.45%)
AAPL   163.94 (+2.31%)
MSFT   331.12 (-1.64%)
FB   327.49 (-3.12%)
GOOGL   2,850.95 (-2.05%)
AMZN   3,508.17 (-1.50%)
TSLA   1,132.11 (-0.43%)
NVDA   322.53 (-3.36%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.46 (-5.42%)
AMD   157.27 (-2.87%)
GE   94.86 (-3.60%)
MU   84.83 (-1.52%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,592.41 (-1.35%)
DOW   34,632.41 (-1.43%)
QQQ   393.90 (-1.45%)
AAPL   163.94 (+2.31%)
MSFT   331.12 (-1.64%)
FB   327.49 (-3.12%)
GOOGL   2,850.95 (-2.05%)
AMZN   3,508.17 (-1.50%)
TSLA   1,132.11 (-0.43%)
NVDA   322.53 (-3.36%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.46 (-5.42%)
AMD   157.27 (-2.87%)
GE   94.86 (-3.60%)
MU   84.83 (-1.52%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,592.41 (-1.35%)
DOW   34,632.41 (-1.43%)
QQQ   393.90 (-1.45%)
AAPL   163.94 (+2.31%)
MSFT   331.12 (-1.64%)
FB   327.49 (-3.12%)
GOOGL   2,850.95 (-2.05%)
AMZN   3,508.17 (-1.50%)
TSLA   1,132.11 (-0.43%)
NVDA   322.53 (-3.36%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.46 (-5.42%)
AMD   157.27 (-2.87%)
GE   94.86 (-3.60%)
MU   84.83 (-1.52%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
NASDAQ:APVO

Aptevo Therapeutics News Headlines

$9.80
-0.73 (-6.93%)
(As of 11/30/2021 01:49 PM ET)
Add
Compare
Today's Range
$9.50
$11.27
50-Day Range
$6.48
$17.49
52-Week Range
$6.38
$51.75
Volume
107,010 shs
Average Volume
9.99 million shs
Market Capitalization
$48.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
6.74

Media Mentions By Week



Aptevo Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

APVO
News Sentiment

-0.09

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

APVO Articles
This Week

1

0

APVO Articles
Average Week

Get Aptevo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

Aptevo Therapeutics (NASDAQ:APVO) News Headlines Today

SourceHeadline
msn.com logoAptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial
msn.com - November 23 at 2:27 PM
finance.yahoo.com logoAptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
finance.yahoo.com - November 23 at 9:25 AM
MarketBeat logoKevin C. Tang Sells 255,331 Shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock
americanbankingnews.com - November 22 at 8:10 PM
MarketBeat logoKevin C. Tang Sells 369,533 Shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock
americanbankingnews.com - November 22 at 8:10 PM
MarketBeat logoAptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Increase in Short Interest
americanbankingnews.com - November 20 at 2:38 AM
MarketBeat logo Brokerages Expect Aptevo Therapeutics Inc. (NASDAQ:APVO) Will Post Quarterly Sales of $3.40 Million
americanbankingnews.com - November 18 at 2:28 AM
benzinga.com logoAptevo Therapeutics Announces Presentation Of 2 Abstracts At Upcoming American Society Of Hematology Annual Meeting
benzinga.com - November 16 at 7:43 PM
MarketBeat logoZacks: Analysts Anticipate Aptevo Therapeutics Inc. (NASDAQ:APVO) Will Announce Earnings of -$1.41 Per Share
americanbankingnews.com - November 16 at 5:20 PM
MarketBeat logoAptevo Therapeutics (NASDAQ:APVO) PT Lowered to $36.00 at Roth Capital
americanbankingnews.com - November 15 at 11:07 AM
benzinga.com logoAlligator Bioscience, Aptevo Therapeutics Announce Poster Presentation Of ALG.APV-527 At SITC Annual Meeting 2021
benzinga.com - November 13 at 1:39 PM
finance.yahoo.com logoAptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
finance.yahoo.com - November 12 at 9:46 AM
finance.yahoo.com logoAlligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
finance.yahoo.com - November 11 at 6:10 PM
finance.yahoo.com logoAptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
finance.yahoo.com - November 11 at 1:10 PM
finance.yahoo.com logoAptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
finance.yahoo.com - October 27 at 10:32 AM
finance.yahoo.com logoAptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
finance.yahoo.com - October 26 at 9:14 AM
finance.yahoo.com logoAptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
finance.yahoo.com - September 28 at 10:07 AM
finance.yahoo.com logoAptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
finance.yahoo.com - August 17 at 3:57 PM
finance.yahoo.com logoAptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
finance.yahoo.com - August 12 at 4:10 PM
finance.yahoo.com logoAptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
finance.yahoo.com - July 16 at 10:20 AM
finanznachrichten.de logoAptevo Therapeutics Announces Inclusion in the Russell Microcap Index
finanznachrichten.de - June 29 at 8:20 AM
finance.yahoo.com logoAptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
finance.yahoo.com - June 29 at 8:20 AM
bizjournals.com logoAptevo CEO says Seattle biotech scene is 'robust and growing'
bizjournals.com - June 25 at 11:56 PM
benzinga.com logoAptevo Therapeutics Insights: Return On Capital Employed
benzinga.com - June 18 at 12:53 PM
benzinga.com logoLooking Into Aptevo Therapeutics's Return On Capital Employed
benzinga.com - June 4 at 2:58 PM
marketwatch.com logoAPTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Regulation FD Disclosure
marketwatch.com - May 30 at 12:52 AM
finance.yahoo.com logoAptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
finance.yahoo.com - May 27 at 9:16 AM
finance.yahoo.com logoAptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
finance.yahoo.com - May 26 at 3:42 PM
finance.yahoo.com logoAptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
finance.yahoo.com - May 26 at 10:26 AM
finance.yahoo.com logoAmerican Eagle Completes Magnetotelluric Survey at its Golden Trend Property in the Cortez, Nevada; Publishes Interview with CEO Anthony Moreau and VP of Exploration Mark Bradley
finance.yahoo.com - May 17 at 6:29 AM
finance.yahoo.com logoAptevo Therapeutics Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 11 at 10:16 AM
finance.yahoo.com logoAptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
finance.yahoo.com - April 9 at 2:11 PM
finance.yahoo.com logoAptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 31 at 9:22 AM
finanznachrichten.de logoAptevo Therapeutics: Aptevo Confirms Receipt of Nominations and Proposal Notice
finanznachrichten.de - February 9 at 9:29 PM
finance.yahoo.com logoAptevo Confirms Receipt of Nominations and Proposal Notice
finance.yahoo.com - February 9 at 9:29 PM
finance.yahoo.com logoAptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why
finance.yahoo.com - January 6 at 2:34 PM
finance.yahoo.com logoKaskela Law LLC Announces Investigation of Aptevo Therapeutics Inc. (APVO) and Encourages Shareholders to Contact the Firm
finance.yahoo.com - December 19 at 6:47 PM
finance.yahoo.com logoAptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
finance.yahoo.com - December 2 at 10:01 AM
finanznachrichten.de logoAptevo Therapeutics: Aptevo Confirms Receipt of Unsolicited Indication of Interest
finanznachrichten.de - November 21 at 10:28 PM
finance.yahoo.com logoAptevo Confirms Receipt of Unsolicited Indication of Interest
finance.yahoo.com - November 19 at 6:43 PM
seekingalpha.com logoAptevo gets $50/share takeout offer from shareholder Tang
seekingalpha.com - November 18 at 10:30 PM
nasdaq.com logoAptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
nasdaq.com - November 16 at 12:19 PM
finance.yahoo.com logoAptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development
finance.yahoo.com - November 16 at 12:19 PM
benzinga.com logoAptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update
benzinga.com - November 10 at 6:44 PM
seekingalpha.com logoAptevo's lead drug achieves second remission in early-stage study
seekingalpha.com - November 9 at 1:37 PM
finance.yahoo.com logoAptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting
finance.yahoo.com - November 9 at 1:37 PM
msn.com logo28 Stocks Moving in Monday's Pre-Market Session
msn.com - November 9 at 8:37 AM
seekingalpha.com logoAptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake
seekingalpha.com - November 9 at 8:37 AM
seekingalpha.com logoAptevo's lead drug achieves second remission in early-stage blood cancer study
seekingalpha.com - November 9 at 8:37 AM
finance.yahoo.com logoAptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
finance.yahoo.com - November 9 at 8:36 AM
finance.yahoo.com logoAptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan
finance.yahoo.com - November 9 at 12:06 AM
Get Aptevo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.